The utilization of imatinib to treat patients with chronic myeloid leukemia (CML) carrying the t(9;22) translocation that produces the BCR-ABL fusion kinase was the first example (7). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.